A Multicenter, Retrospective, Observational Study Using Real-world Data to Describe the Safety, Treatment Pattern and Effectiveness of Nirmatrelvir/Ritonavir among Patients treated with Nirmatrelvir/Ritonavir in China

First published: 16/03/2023 Last updated: 26/11/2024





Administrative details

EU PAS number

EUPAS103409

Study ID

103410

DARWIN EU® study

No

Study countries

$\overline{}$
а
S

Study status

Finalised

Research institutions and networks

Institutions

Guangzhou Medical University

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Multiple centres: 9 centres are involved in the

study

Contact details

Study institution contact

Ying Ma ying.ma3@pfizer.com

Study contact

ying.ma3@pfizer.com

Primary lead investigator

Nanshan Zhong

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 08/09/2022

Study start date

Planned: 06/03/2023

Actual: 05/12/2022

Data analysis start date

Actual: 26/02/2024

Date of interim report, if expected

Actual: 25/07/2023

Date of final study report

Planned: 17/04/2024

Actual: 07/06/2024

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Pfizer

Study protocol

C4671043 Protocol-5Dec2022-Redacted.pdf (7.32 MB)

C4671043_Protocol-5Dec2022-full protocol.pdf (7.31 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Study design:

Retrospective observational study

Main study objective:

To describe real-world safety of nirmatrelvir/ritonavir among patients treated with nirmatrelvir/ritonavir in China.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Retrospective observational study

Study drug and medical condition

Name of medicine

PAXLOVID

Study drug International non-proprietary name (INN) or common name

NIRMATRELVIR

RITONAVIR

Anatomical Therapeutic Chemical (ATC) code

(J05AE30) nirmatrelvir and ritonavir nirmatrelvir and ritonavir

Medical condition to be studied

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

1000

Study design details

Outcomes

Incidence of AEs and SAEs with explicit attribution to nirmatrelvir/ritonavir, Proportion of patients with nirmatrelvir/ritonavir dose change due to AEs with explicit attribution to nirmatrelvir/ritonavir, Proportion of patients experiencing safety related scenarios; Treatment patterns endpoints include proportion and/or duration of nirmatrelvir/ritonavir, and/or concomitant COVID-19-related treatments, or other concomitant treatments. Effectiveness endpoints include COVID-19 disease severity progressed or death, time to alleviation of signs/symptoms, Proportion of patients with consecutive negative tests and time to first negative test.

Data analysis plan

This study is descriptive in nature and no formal hypothesis testing will be conducted. Continuous variables will be summarized using n, mean, median,

minimum, maximum, standard deviation (SD), and 25th and 75th percentiles, and in addition, 95% CI will be provided for effectiveness variables. Categorical variables will be summarized using number and percentages of each category. For continuous and categorical variables, missing data will not be imputed and will be reported as frequency and percentage. Missing data will not be included in the summary statistics. For time-to-event variables (such as time to alleviation of all targeted COVID-19 signs and symptoms), Kaplan Meier (K-M) plots will be generated, and median time will be estimated along with the corresponding 95% CI.

Documents

Study report

C4671043 Paxlovid NI Clinical Study Report_redacted.pdf (805.02 KB)
C4671043 Paxlovid NI Clinical Study Report Abstract redacted.pdf (400.64 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Data sources (types)

Other

Data sources (types), other

Individual-level data will be retrospectively abstracted from Hospital Information System (HIS) and Laboratory Information System (LIS) to the electronic Case Report Form (eCRF).

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Not applicable